– USA, MA – Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Robertson to its Board of Directors, effective November 15, 2021, replacing Gina Consylman, who is stepping down from the Board.
“We look forward to welcoming Michelle as Verastem continues to rapidly advance its development program in RAS targeted treatment. Michelle’s extensive leadership in Finance and Commercial Operations for leading biotechnology companies will be an asset to our Board,” said Lead Director, Dr. Michael Kauffman.
Ms. Robertson, who is CFO at Editas Medicine, will chair the audit committee.
About
Before joining Editas Medicine as its CFO, Ms. Robertson served as CFO of Momenta Pharmaceuticals, Inc. before its acquisition by Johnson & Johnson in 2020. She joined Momenta as VP, Financial Planning and Analysis. Previously, she served as VP of Oncology Finance for Baxalta, Inc., which was acquired by Shire PLC in 2016, following its spin-out from Baxter International in July 2015. She also served as head of Financial Planning and Analysis and Operations at Ironwood Pharmaceuticals and has held various leadership positions in the Oncology and Biosurgery divisions with Finance and Commercial Operations at Genzyme, focusing on financial analysis for business development, acquisition integrations, and divestitures.
“Verastem’s work to bring new treatment options to patients with RAS pathway-driven cancers is inspiring, and I am energized to join the Board of Directors at such an exciting time,” commented Ms. Robertson. “Their progress to date and future potential are built on excellent science, a focused development strategy, and a highly committed team. I look forward to supporting the Company’s continued advancement.”
Ms. Robertson received her BS in Finance from Bentley University.
About Verastem Oncology
Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase inhibition.
For more information: https://www.verastem.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.